ArticlePloS one2025
Divergent impacts of glycemic control on mortality and complications in patients with early-versus late-onset type 2 diabetes: A retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate whether optimal glycemic control is associated with all-cause mortality, cardiovascular disease mortality, diabetes-related mortality, cancer-related mortality, and complications among individuals with early-onset and late-onset T2D.
methodsWe conducted a retrospective cohort study using data from the U.S. National Health and Nutritional Examination Survey (NHANES)1999-2818. Optimal glycemic control was defined as HbA1c<7%, and poor glycemic control as HbA1c≥9%. Mortality and underlying causes of death were ascertained by linkage to national death records through 31 December 2019. Cox proportional hazards regression models adjusted for age, sex, race, education, body mass index (BMI), hypertension, smoking status, alcohol consumption, and physical activity were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between HbA1c levels and mortality. Logistic regression models with the same covariates were employed to calculate odds ratios (ORs) and 95% CIs for complications, supplemented by sensitivity analyses to evaluate the robustness of the findings.
resultsAmong the 5946 participants with diabetes, 18.8% were classified as having early-onset T2D (aged < 40 years), 28.7% as having late-onset T2D (aged ≤ 60 years), and 52.5% had average-onset T2D. For individuals with early-onset T2D, the poorly controlled group (HbA1c≥9%) had HRs of 2.00 (95% CI, 1.30-3.09; P = 0.002) for all-cause mortality and 10.04 (95% CI, 2.57-39.32; P = 0.001) for diabetes-related mortality versus the optimal controlled group (HbA1c<7%). The poorly controlled group had odds of 1.80 (95% CI, 1.10-2.94; P = 0.022) for retinopathy and 2.54 (95% CI, 1.65-3.92; P < 0.001) for chronic kidney disease (CKD) versus the optimal controlled group. For individuals with late-onset T2D, the HRs were 0.87 (HR 0.87; 95% CI, 0.54-1.40; P = 0.561) for all-cause mortality and 1.24 (95% CI, 0.33-4.67; P = 0.751) for diabetes-related mortality compared with the optimal controlled group. The poorly controlled group had odds of 2.12 (95% CI, 1.32-3.41; P = 0.002) for retinopathy and 2.30 (95% CI, 1.45-3.63; P = 0.001) for CKD versus the optimal controlled group.
conclusionOptimal glycemic control was associated with a reduced risk of all-cause mortality, diabetes-related mortality, retinopathy, and CKD in individuals with early-onset T2D; however, in individuals with late-onset T2D, this correlation was limited to lower risks of retinopathy and CKD. These findings suggest that glycemic control strategies should be tailored on the basis of the age of diabetes onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.